{
  "abstract": "Objective To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA).Methods This post hoc analysis primarily used data from the phase 3 KEEPsAKE 1 trial of adult patients with PsA, with data from KEEPsAKE 2 pooled for prespecified outcomes. Outcomes measuring risankizumab efficacy across key GRAPPA-recognised domains of PsA (peripheral arthritis, enthesitis, dactylitis, skin and nail psoriasis, axial disease) and PsA-related conditions such as inflammatory bowel disease (IBD) and uveitis were assessed over 100 weeks of treatment (~2 years). Statistical approaches included non-responder imputation (as-observed with imputation) for categorical variables and mixed-effect model for repeated measures for continuous variables including as-observed measurements at all visits. PsA-related conditions were evaluated via adverse events through 100 weeks.Results Overall, in KEEPsAKE 1 and KEEPsAKE 2, 412/483 (85.3%) and 181/224 (80.8%) of patients randomised to risankizumab completed treatment to week 100. Risankizumab demonstrated efficacy across all GRAPPA-defined domains through 100 weeks, including swollen and tender joint counts, enthesitis, dactylitis, skin and nail outcomes, and axial disease. In KEEPsAKE 1, 42.4% of patients had achieved a Disease Activity in Psoriatic Arthritis measurement of low disease activity and 62.9% had reached a minimal clinically important difference in pain at week 100. Rates of new onset or flare of IBD and uveitis were low.Conclusions Treatment with risankizumab provides durable improvement in the signs and symptoms of PsA across all GRAPPA disease domains and related conditions.",
  "authors": [
    {
      "affiliations": [
        "Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"
      ],
      "name": "Laura C Coates"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain",
        "Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain"
      ],
      "name": "Ricardo Blanco"
    },
    {
      "affiliations": [
        "Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany",
        "Department of Rheumatology, Goethe University Frankfurt, Frankfurt am Main, Germany"
      ],
      "name": "Frank Behrens"
    },
    {
      "affiliations": [
        "University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"
      ],
      "name": "Alexis Ogdie"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Ghent University, Ghent, Belgium"
      ],
      "name": "Filip Van den Bosch"
    },
    {
      "affiliations": [
        "Department of Rheumatology Unit, Hospital das Clínicas, Federal University of Uberlândia, Uberlândia, Brazil"
      ],
      "name": "Roberto Ranza"
    },
    {
      "affiliations": [
        "Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA"
      ],
      "name": "Yael Klionsky"
    },
    {
      "affiliations": [
        "AbbVie Inc, North Chicago, Illinois, USA"
      ],
      "name": "Ahmed M Soliman"
    },
    {
      "affiliations": [
        "AbbVie Inc, North Chicago, Illinois, USA"
      ],
      "name": "Michael Chen"
    },
    {
      "affiliations": [
        "AbbVie Inc, North Chicago, Illinois, USA"
      ],
      "name": "Derek Coombs"
    },
    {
      "affiliations": [
        "AbbVie Inc, North Chicago, Illinois, USA"
      ],
      "name": "Linyu Shi"
    },
    {
      "affiliations": [
        "AbbVie Inc, North Chicago, Illinois, USA"
      ],
      "name": "Jamie R Urbanik"
    },
    {
      "affiliations": [
        "AbbVie Inc, North Chicago, Illinois, USA"
      ],
      "name": "Thomas Iyile"
    },
    {
      "affiliations": [
        "AbbVie Inc, North Chicago, Illinois, USA"
      ],
      "name": "Ralph Lippe"
    },
    {
      "affiliations": [
        "INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France",
        "APHP, Department of Rheumatology, Hopital Universitaire Pitie Salpetriere, Paris, France"
      ],
      "name": "Laure Gossec"
    }
  ],
  "title": "Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies",
  "uid": "1ada47dc-8216-56bf-97c5-ee0f6f3d3174"
}